surmount-1 trial tirzepatide obesity without diabetes weight loss π Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but diabetes. Researchers Gastrointestinal tolerability and weight reduction
Pay in 4 interest-free payments of $5.11 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 16 - Aug 21























